



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

<b>Project title</b>	Innovating the Delivery and Capacity Expansion of Macular Services for the People of Greater Manchester
<b>Project partners</b>	Central Manchester University Hospital NHS Foundation Trust Bayer plc
<b>Project summary</b>	<p>Central Manchester University Hospital NHS Foundation Trust and Bayer plc are working in partnership under a joint working agreement to increase the capacity of the macular service through the creation of community high street services in the north and the south of the city.</p> <p>The increased capacity in the macular clinic will aim to improve patient care by increasing the percentage of medical retina patients being diagnosed and offered treatment in line with national guidelines on time intervals. The new high street services will improve patient flow through the clinic and will result in an improved patient experience.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b>Benefits to Patients:</b></p> <ul style="list-style-type: none"><li>• Long term macular service in convenient locations</li><li>• Care adhering to NICE guidelines providing optimal outcomes</li><li>• Quicker patient journey and improved experience through the macular clinic for each appointment</li><li>• Quicker access and transit into the clinic and necessary arrangements if patients need to access by ambulance</li><li>• Additional shopping and rest/refreshment facilities to enhance patient visits to clinics, and improve experience for carers</li></ul> <p><b>Benefits to the NHS:</b></p> <ul style="list-style-type: none"><li>• Care closer to home for medical retina patients in line with local Commissioners' request and expectations</li><li>• Delivery of the treatment targets set by local Commissioners</li><li>• Delivery of services into community settings in line with the priorities of the Greater Manchester NHS</li><li>• Longevity of community service which has further expansion capability and permanency in location</li></ul>

	<p><b>Benefits to Bayer:</b></p> <ul style="list-style-type: none"> <li>• Enhanced reputation by demonstrating commitment and willingness to invest in improving patient care through a fully transparent joint working agreement with Manchester</li> <li>• Inputting, shaping and learning from the implementation of a large, strategic, complex project which is innovative in its approach but offers Greater Manchester medical retina patients significant advantages</li> <li>• Improving NICE-approved medicines optimisation of injectable therapies, of which Bayer's aflibercept is one</li> </ul>
<b>Start date</b>	August 2017

Date of Preparation: May 2019  
Job bag number: PP-OTH-GB-0195